Get App
Moneycontrol

Co-Partners

Associate Partners

Last Updated : May 15, 2019 09:37 AM IST | Source: Moneycontrol.com

Orchid Pharma locked at upper circuit on USFDA nod

The company has received ANDA approval from USFDA for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Orchid Pharma locked at upper circuit on May 15 on the back of USFDA nod for Risedronate Sodium Tablets.

At 09:24 hrs Orchid Pharma was quoting at Rs 4, up Rs 0.17, or 4.44 percent.

There were pending buy orders of 33,257 shares, with no sellers available.

The company has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

orchid

For more market news, click here

Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.
First Published on May 15, 2019 09:36 am
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant